Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists As Potential Migrastatics for Triple Negative Breast Cancer

Researchers reported the synthesis and biological evaluation of fluorine-containing triazole derivatives as potent lysophosphatidic acid receptor 1 (LPA1) antagonists, offering potential as migrastatic drugs for triple negative breast cancer.